Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.